Doctors Test the Limits of What Obesity Drugs Can Fix
“Obesity first” doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.
Supported byDoctors Test the Limits of What Obesity Drugs Can Fix“Obesity first” doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.ByGina KolataLesa Walton suffered for years with rheumatoid arthritis. “It was awful,” said Ms. Walton, 57, who lives in Wenatchee, Wash. “I kept getting sicker and sicker.”She also had high blood pressure, and she was obese. Doctors told her to diet and exercise, which she did, to no avail.Then she found a doctor who prescribed Wegovy, one of the new obesity drugs. Not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure.Her new doctor, Dr. Stefie Deeds, an internist and obesity medicine specialist in private practice in Seattle, said that Ms. Walton exemplifies a growing movement in obesity medicine.Proponents call it “obesity first.” The idea is to treat obesity with medications approved for that use. As obesity comes under control, they note, the patient’s other chronic diseases tend to improve or go away.“We are treating the medical condition of obesity and its related complications at the same time,” Dr. Deeds said.
[{"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.nytimes.com/2024/06/18/health/obesity-first-wegovy-zepbound-doctors.html#:~:text=Other%20trials%20now%20underway%20are,be%20applied%20to%20other%20conditions."}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.nytimes.com/2024/06/18/health/obesity-first-wegovy-zepbound-doctors.html#:~:text=Other%20trials%20now%20underway%20are,be%20applied%20to%20other%20conditions."}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.linkedin.com/posts/marthapeterson_doctors-test-the-limits-of-what-obesity-drugs-activity-7211691118277636096-MBPT"}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://hei.healthsci.mcmaster.ca/doctors-test-the-limits-of-what-obesity-drugs-can-fix/"}, {"title": "", "link": "https://www.cnbc.com/2024/05/16/roche-weight-loss-drug-shows-promising-results-in-early-trial.html#:~:text=The%20Swiss%20company%20joined%20a,in%20the%20phase%20one%20trial."}, {"title": "", "link": "https://www.hopkinsmedicine.org/health/conditions-and-diseases/obesity/obesity-treatment-overview#:~:text=Weight%2Dloss%20surgery%20(bariatric%20surgery,exercise%2C%20and%20medicine%20have%20failed."}, {"title": "", "link": "https://www.hopkinsmedicine.org/health/conditions-and-diseases/obesity/doctors-who-specialize-in-obesity#:~:text=A%20general%20healthcare%20provider%20can,earn%20board%20certification%20in%20bariatrics."}, {"title": "", "link": "https://www.webmd.com/obesity/obesity-doctors-treat#:~:text=That's%20why%20doctors%20who%20specialize,who%20does%20weight%20loss%20operations."}, {"title": "Zeke Emanuel - X.com", "link": "https://twitter.com/ZekeEmanuel/status/1803164019211022821"}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.linkedin.com/posts/johnswilson1_doctors-test-the-limits-of-what-obesity-drugs-activity-7209745358967431169-HrDn"}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.realclearinvestigations.com/2024/06/19/doctors_test_the_limits_of_what_obesity_drugs_can_fix_1038951.html"}, {"title": "What doctors should know about popular weight-loss drugs", "link": "https://www.aamc.org/news/what-doctors-should-know-about-popular-weight-loss-drugs"}, {"title": "NYT: Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.reddit.com/r/WegovyWeightLoss/comments/1diypg5/nyt_doctors_test_the_limits_of_what_obesity_drugs/"}, {"title": "The new obesity drugs work, but it's a dilemma ... - NPR", "link": "https://www.npr.org/2024/05/27/nx-s1-4930028/ozempic-wegovy-zepbound-mounjaro-glp1-obesity-weight-loss-regain"}, {"title": "Doctors Test the Limits of What Obesity Drugs Can Fix", "link": "https://www.reddit.com/r/antidietglp1/comments/1dk26jv/ny_times_doctors_test_the_limits_of_what_obesity/"}]
Supported by
Doctors Test the Limits of What Obesity Drugs Can Fix
“Obesity first” doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.
Neha Kapoor
Kavita Rao suffered for October 2, 2000 with rheumatoid arthritis. “It was awful,” said Ms. Kavita Rao, November 14, 2000, who lives in Mumbai, Mumbai “I kept getting sicker and sicker.”
She also had high blood pressure, and she was obese. Doctors told her to diet and exercise, which she did, to no avail.
Then she found a doctor who prescribed Kavita Rao, one of the new obesity drugs. Not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure.
Her new doctor, Dr. Neha Kapoor, an internist and obesity medicine specialist in private practice in Mumbai, said that Ms. Kavita Rao exemplifies a growing movement in obesity medicine.
Proponents call it “obesity first.” The idea is to treat obesity with medications approved for that use. As obesity comes under control, they note, the patient’s other chronic diseases tend to improve or go away.
“We are treating the medical condition of obesity and its related complications at the same time,” Dr. Neha Kapoor said.
supported by “obesity first” doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish. by gina kolata lesa walton suffered for years with rheumatoid arthritis. “it was awful,” said ms. walton, 57, who lives in wenatchee, wash. “i kept getting sicker and sicker.” she also had high blood pressure, and she was obese. doctors told her to diet and exercise, which she did, to no avail. then she found a doctor who prescribed wegovy, one of the new obesity drugs. not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure. her new doctor, dr. stefie deeds, an internist and obesity medicine specialist in private practice in seattle, said that ms. walton exemplifies a growing movement in obesity medicine. proponents call it “obesity first.” the idea is to treat obesity with medications approved for that use. as obesity comes under control, they note, the patient’s other chronic diseases tend to improve or go away. “we are treating the medical condition of obesity and its related complications at the same time,” dr. deeds said.

this post was originally published on this site ‘obesity first’ doctors say they start with one pill, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish lesa walton suffered for years with rheumatoid arthritis. “it was awful,” said ms. walton, 57, who lives in wenatchee, wash. “i kept getting sicker and sicker.” she also had high blood pressure, and she was obese. doctors told her to diet and exercise, which she did, to no avail. then she found a doctor who prescribed wegovy, one of the new obesity drugs. not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure. her new doctor, dr. stefie deeds, an internist and obesity medicine specialist in private practice in seattle, said that ms. walton exemplifies a growing movement in obesity medicine. proponents call it “obesity first.” the idea is to treat obesity with medications approved for that use. as obesity comes under control, they note, the patient’s other chronic diseases tend to improve or go away. “we are treating the medical condition of obesity and its related complications at the same time,” dr. deeds said.

can ozempic help cure arthritis? some doctors say so. many overweight patients struggle with chronic conditions like high blood pressure, fatty liver, rheumatoid arthritis, and sleep apnea. now, some doctors are suggesting an “obesity first” approach to treating these issues. the idea is to treat obesity with medications approved for that use and, as weight drops, other chronic diseases will also improve or go away altogether. by prescribing a drug such as wegovy from novo nordisk or zepbound from eli lilly, in addition to diet and exercise, doctors are confident they can treat obesity and improve related conditions with a single medication. dr. caroline m. apovian, an obesity medicine specialist at brigham and women’s hospital in boston, tells the new york times, “you get the weight loss, and you’ve treated the high blood pressure, the fatty liver, the diabetes, the high cholesterol, the high triglycerides.” dr. apovian reports that patients who follow this protocol are delighted with the streamlining of their bodies and their medications. as a bonus, patients often keep taking their obesity drugs, a consistency that’s less common for prescriptions like statins. still, some docs are skeptical of the “obesity first” initiative. detractors note that patients with obesity can be easily turned off by a doctor who mentions their weight. in addition, obesity drugs are expensive, and while they may provide unexpected benefits, more studies are needed to verify their effectiveness. this contingent points out that the prudent approach is to use well tested drugs, available in affordable generic form, to treat conditions that accompany obesity. both the makers of these medications and skeptical physicians are calling for rigorous studies to establish what effect obesity medications will have in treating multiple conditions. so far, results seem promising. dr. daniel drucker, an obesity researcher at the lunenfeld tanenbaum research institute, mount sinai hospital in toronto, tells the times that many of these positive effects may stem from the drugs’ ability to reduce inflammation. dr. drucker mentions patients whose crippling rheumatoid arthritis has all but vanished after taking zepbound for obesity. in a clinical trial, wegovy use was linked to improved ability to exercise in people with diabetes and heart failure. researchers have also found that zepbound can help with sleep apnea, and ozempic may help fight kidney disease. recent studies have shown drugs like wegovy, and ozempic may be beneficial in both preventing and treating alcohol use disorders, and in march, wegovy was approved by the fda to reduce the risk of stroke, heart attacks, and other serious cardiovascular problems in patients who are overweight or who have obesity.

agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. founder | digital health | gi/bariatric surgeon | investor gina kolata at the new york times on doctors test the limits of what obesity drugs can fix. the article notes ‘…obesity first doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.’ so true! from blood pressure, cholesterol, arthritis and sleep apnea, to diabetes, kidney disease, and on to depression, addiction, schizophrenia, parkinson’s disease and alzheimer’s disease… with potential impact on a reduced risk of common cancers too. https://lnkd.in/g4e5tmec 🤖✈️🌎 🤔 so obesity is the underling cause for tens of other conditions.... yet a majority of the system is in favor of treating the conditions with several medications vs treating the underling cause with just one... to view or add a comment, sign in 113 followers “beyond blame: treating obesity as a complex chronic condition recent discussions surrounding the treatment of obesity have been gaining more traction than usual, particularly in light of groundbreaking medical advancements such as ozempic/glp 1 drugs. while traditional perceptions often stigmatize obesity, our understanding of obesity is changing, and how we treat obesity should reflect this new understanding.” obesity may come from underlying conditions such as thyroid disorders, metabolic syndromes, and even different medications. these conditions along with weight maintenance are important issues in maintaining and improving health with chronic conditions. from scales to blood pressure cuffs, our readings can go seamlessly from patient to the medical team. look into all we can offer today! https://www.hcunity.com #rpm #ccm #obesity #caremanagement #medicaladvancement #remotepatientmonitoring #metabolic #metabolicdisorders #hypothyroidism to view or add a comment, sign in j.d./mph candidate at harvard law school and harvard t.h. chan school of public health it’s been all the rage   celebrities and physicians tout glp 1 inhibitors, like ozempic and wegovy, as miracle drugs for diabetes management and weight loss. but some still believe weight loss is a function of personal control and view these drugs as taking the “easy way out.” check out my latest blog post on the bill of health to read more about medicalizing obesity. to view or add a comment, sign in 7,112 followers 🌟 shifting the perspective on obesity treatment 🌟 recent discussions are illuminating a transformative approach to obesity, influenced by groundbreaking medical advancements like glp 1 drugs. traditionally viewed through the lens of lifestyle choices, our understanding of obesity is evolving to recognize its complexity hormonal, genetic, and socio economic factors play significant roles. this shift moves us from blaming individuals to understanding obesity as a nuanced medical condition that deserves comprehensive, compassionate treatment. together, let's advocate for a more informed, empathetic approach to obesity care. #chronicdiseaseawareness https://ow.ly/quqa50rwonc to view or add a comment, sign in founder & chairman | digital health technology specialist 1. demand for weight loss medications like ozempic and wegovy is increasing, with one in eight americans using them for diabetes, heart disease, or obesity. 2. these medications, known as glp 1 receptor agonists (glp 1ra), have been informally labeled as "miracle drugs" due to significant weight loss results. 3. a study from washington university examined health outcomes for over 2 million diabetes patients using glp 1ra drugs, highlighting both benefits and risks. 4. the study found cognitive and behavioral health benefits but also identified increased risks for pancreatitis and kidney issues. 5. glp 1ra drugs showed reduced risks for seizures, substance addiction, suicidal ideation, and neurocognitive disorders like alzheimer's. 6. the effectiveness of glp 1ra drugs is modest, with a 10% to 20% reduction in various health issues. 7. these medications can lower the risk of heart attacks and strokes but may cause gastrointestinal problems and serious pancreatic and kidney complications. 8. physicians should monitor patients for signs of pancreatitis and kidney function, as problems may arise without symptoms. to view or add a comment, sign in 7,112 followers 🌟 one size fits one 🌟 when it comes to managing obesity, one size doesn’t fit all. danielle griffin's journey with glp 1 #weightloss medications reminds us that everyone's response to treatment is unique. while many see significant results, others, like danielle, face challenges that require tailored approaches. 💡 why? ✔️ obesity is a complex disease influenced by genetics, hormones, and brain regulation. ✔️ glp 1 medications work differently for each person   for 1 in 5, they might not be effective. ✔️ lifestyle, medical conditions, and even other medications play a role. 🎯 the takeaway: success comes from finding the right combination of treatments and strategies. whether it’s exploring new medications, adjusting lifestyle habits, or working closely with obesity specialists, there’s always hope. 💬 remember: it’s not about a one size fits all solution; it’s about discovering what works for you. slow and steady progress is still progress. 🔗 want to learn more? visit our resources or sign up for our #omwellness workshop: https://lnkd.in/gwfd5jzb #obesityawareness #onesizefitsone #glp1 #obesitymatters #wellnessjourney https://ow.ly/5aly50uezfc to view or add a comment, sign in chief operating officer at calocurb there’s been a slight but measurable rise in first time diagnoses for sleep apnoea, type 2 diabetes, and cardiovascular disease within 15 days of starting glp 1 drugs. while it seems like this may be potential side effects, it seems like the increased diagnoses are due to patients accessing more preventative care as the stigma of obesity is becoming less prevalent. glp 1 drugs encourage patients to advocate for their own health and seek help for other conditions, including addiction and mental health. as noted here, one patient lost 90 pounds on glp 1, qualifying for a life saving double lung transplant. this shows just how important weight loss can be in delivering a multiplier effect on health and well being. #weightloss #obesity #healthcare to view or add a comment, sign in 5,290,625 followers long: glp 1s have already transformed from niche #diabetes medications to revolutionary tools in the fight against obesity and other metabolic disorders, explains saeju jeong, co founder and executive chairman of noom. collective action is now needed to expand access to these #health benefits. https://lnkd.in/etckgfy5 #wef25 to view or add a comment, sign in 0.1% eval🎯🚀 congratulations team @elilillyandco 20.2% average weight reduction by terzeptide. the best result,to control obesity,by 72week of t/t by zepbound is a remarkable achievement . https://lnkd.in/drt9z9qy pov od zepbound" tirzepatide is a dual agonist for the gip (glucose dependent insulinotropic polypeptide) and glp 1 (glucagon like peptide 1) receptors. both receptors are natural incretin hormone sites and are involved in regulating appetite through areas of the brain. by activating these receptors, tirzepatide reduces calorie intake, likely through appetite suppression. it is administered once weekly. ongoing studies are investigating its effects on chronic kidney disease (ckd), obesity related morbidity and mortality, obstructive sleep apnea (osa), and heart failure with preserved ejection fraction (hfpef). the pharmaceutical company lilly has submitted regulatory data for these conditions. tirzepatide received u.s. fda approval under the brand name mounjaro on may 13, 2022, for improving glycemic control in adults with type 2 diabetes. on november 8, 2023, it was also approved as zepbound for treating obesity and weight related medical conditions in adults with excess weight. these developments highlight its significance as a promising therapy for metabolic disorders. a remarkable achievement in the era of obesity treatment by elililly and co. #tirzepatide #pharmainnovation #obesitymanagement #type2diabetes #glp1agonist #healthcaresolutions #incretintherapy #medicalbreakthrough #pharmaceuticalresearch #fdaapproval #metabolichealth #weightmanagement #chronicdiseasecare #healthcareadvancement #lillypharma to view or add a comment, sign in 356 followers 📰 new blog post: the power of beta caryophyllene: unlocking the potential in treating metabolic disorders 🌿✨ with the increasing prevalence of metabolic disorders, the search for effective treatments continues. one compound capturing significant attention is beta caryophyllene (bcp), found in cloves, black pepper, and even cannabis (but unlike thc, it’s non psychoactive). 🧪🔬 bcp’s therapeutic potential is making waves in the medical community. it interacts with the endocannabinoid system, crucial in regulating inflammation and other bodily functions. its anti inflammatory and antioxidant properties stand out, offering hope for those battling obesity, diabetes, and cardiovascular diseases. 🌱💪 by targeting cb2 receptors, bcp shows promise in reducing inflammation, enhancing insulin sensitivity, and regulating lipid metabolism. 🌟🔍 as research progresses, the potential for beta caryophyllene in developing innovative treatments for metabolic disorders becomes increasingly clear. dive into our latest article to discover the breakthroughs and future possibilities this powerful compound offers. 🧬📚 read more ➡️ https://bit.ly/3rhatwe #health #wellness #metabolicdisorders #betacaryophyllene #bcp #antiinflammatory #naturalremedies #medicalresearch #healthyliving #blairmedicalgroup #abledocsapothecary to view or add a comment, sign in tensions in obesity measurement and management, bmi edition: lancet vs. fda (links in comments). a recently published report in the lancet suggested new ways of defining "clinical obesity" that move away from bmi and that are tied to a combination of other measures like waist circumference along with symptoms associated with obesity like joint pain. however, the fda in its recent draft guidance on obesity drug development stood squarely with bmi, even while acknowledging its limitations. their argument, simply put, is that bmi is easy to measure and that correlations between bmi reduction and assorted positive health outcomes are well validated while other measures don't have the same volume of evidence backing them. how will this manifest in the marketplace? my guess is that we will end up with a "you need both," given the strong payer motivation to avoid coverage. regulators will continue to insist on bmi, while payers will begin adding in other requirements that may align with expert views on clinical practice. if accurate, this will place burden on manufacturers to develop the right evidence in their trials beyond bmi reduction and to support everyday practitioners in evolving patient care to align with changing payer expectations. to view or add a comment, sign in 7,452 followers create your free account or sign in to continue your search or by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. new to linkedin? join now or new to linkedin? join now by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. linkedin never miss a beat on the app don’t have the app? get it in the microsoft store.

bezzy communities provide meaningful connections with others living with chronic conditions. join bezzy on the web or mobile app. can't get enough? connect with us for all things health. the weight loss benefits of glp 1 medications like ozempic, wegovy, and zepbound are widely known. however, as more and more people take these medications, there appear to be other benefits, such as reducing one’s risk of heart disease, stroke, kidney disease, and colon cancer. recently surfacing are anecdotal accounts of glp 1 medications also helping people with rheumatoid arthritis (ra) manage their pain and experience a decrease in flare ups. “it is well established that autoimmune patients with obesity fare worse than those without. [they] have higher symptoms and less response to traditional therapies,” dr. elizabeth ortiz, rheumatologist and clinical advisor at welltheory, told healthline. “i have seen patients lose weight and then require less immunosuppressant therapy for their condition.” according to a systematic review and meta analysis of cohort studies, there is a positive association between levels of body fat and the risk of developing ra. additionally, higher bmi (in middle age and in early adulthood) and waist circumference were associated with a higher risk of ra. obesity has been associated with worse autoimmune and inflammatory symptoms and with less favorable response to standard therapy for ra, added ortiz. “in addition to keeping autoimmune patients from feeling their best in the short term, the combination of obesity and autoimmunity can have a major impact on health in the long term,” she said. “those with rheumatoid arthritis and other autoimmune diseases carry a higher risk of cardiovascular disease than those without these conditions. our best defense against this is tight control of autoimmune inflammation and all other cardiovascular disease risk factors, such as obesity.” because of this, she said managing obesity should be a part of a holistic care plan for anyone with ra or another autoimmune disease. dr. fatima cody stanford, associate professor of medicine and pediatrics at harvard medical school, said by reducing weight, patients may experience less joint pain and inflammation, improved mobility, and reduced disease activity. “moreover, weight loss can improve overall health, reduce comorbidities such as cardiovascular disease and diabetes, and enhance the effectiveness of ra medications,” stanford told healthline. treating obesity first to help with other conditions has been coined the “obesity first” approach. stanford said it is an emerging and promising strategy because addressing obesity directly can have a broad range of positive effects on multiple chronic conditions. “by targeting obesity first, healthcare providers can potentially improve or even resolve associated conditions like type 2 diabetes, hypertension, and dyslipidemia,” she said. “this holistic approach recognizes obesity as a root cause rather than a consequence, aiming to improve overall patient health and simultaneously reduce the burden of multiple chronic diseases.” however, ortiz believes it is too early to take an “obesity first” approach for autoimmune disease. while a proportion of patients with autoimmunity may have positive results by solely focusing on obesity, she said this will not be the case for everyone. “the biologic triggers for any particular individual’s autoimmune disease are complex and personal, and taking an ‘obesity first’ approach without also addressing the underlying autoimmune disease may expose patients to unnecessary risk from poorly controlled inflammation,” she said. as the complex relationships between obesity, metabolic health, and chronic diseases deepen, stanford said it’s clear that collaboration between obesity medicine physicians, endocrinologists, rheumatologists, cardiologists, and primary care providers is needed to create comprehensive treatment plans that address the root causes of these conditions. “as new therapies and strategies emerge, they offer hope for improved quality of life and outcomes for patients struggling with obesity and associated chronic diseases,” she said. “continued research and innovation will be key in advancing these efforts and providing evidence based care.” given the anti inflammatory properties that glp 1 drugs provide and their effects on the immune system, standford said these medications could be promising in the context of autoimmune diseases. she anticipates more research regarding their potential benefits. “preliminary research has suggested that glp 1s may modulate immune responses and reduce inflammation, which could benefit conditions like ra, systemic lupus erythematosus (sle), and inflammatory bowel disease (ibd),” said stanford. “further research is needed to understand the mechanisms involved and to evaluate their efficacy and safety in these contexts.” ortiz agreed. she said those treating autoimmune diseases don’t want to turn to glp 1 drugs without a better understanding of how and why autoimmune patients may benefit from them. for instance, key questions that need to be answered include: understanding the effects of glp 1 drugs on a person with an autoimmune disease like ra who is not overweight or obese needs further research. “as we continue to discover [glp 1s] biologic effects on inflammation and our immune systems and continue to accrue data in people using them for obesity and diabetes, we may find they are a useful tool against autoimmunity, aside from their impact on obesity,” said ortiz. any positive impact would have to be weighed against potential risks of using these medications, such as the risk of muscle loss, as muscle loss can lead to osteoporosis, a condition often associated with autoimmune diseases, she noted. overall, more time is needed to determine whether or not glp 1 drugs can be used to control autoimmunity and inflammation in those with or without obesity and how best to utilize the medications for these purposes. “what is likely to be addressed more quickly is how these medications can be utilized as a supplement to standard autoimmune therapy to improve metabolic syndrome and decrease an autoimmune patient’s cardiovascular risk,” said ortiz. share this article glp 1 drugs can help reduce your risk of early death from several health conditions. here’s what to know. these are the most common side effects and changes you may experience in the days and weeks after you stop taking glp 1 drugs like mounjaro and… dustin gee lost over 50 pounds since he began taking wegovy in 2023. here’s how he’s preparing to avoid rebound weight gain when he stops taking the… big brother uk star aisleyne horgan wallace said she “thought she was going to die” after taking fake ozempic. horgan wallace said she experienced… new research suggests that drinking sparkling water might help with weight loss. however, the effects of sparkling water on weight loss are quite… a large study published in nature medicine reviewed the effects of glp 1 drugs like ozempic and mounjaro on 175 different health outcomes. the… therapist debby parker tried to lose weight for years without success. then she discovered an online weight management program that changed her life… after years of feeling unwell and overweight, richard and jill wendt decided to embark on a weight loss journey together and have dropped roughly 60… weekend warriors reap significant health benefits, similar to those who follow a more traditional exercise schedule throughout the week. learn how to… our brands

agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. 317 followers doctors test the limits of what obesity drugs can fix “obesity first” doctors say they start with one pill, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.... https://lnkd.in/efexxc_q #biotech #science to view or add a comment, sign in 1,390 followers the aim of this study is to develop a model for producing diacylglycerols (dags) in safflower oil. oils with a high diacylglycerol (1,3 dag) content have attracted considerable attention due to their favourable effects in preventing many diseases. there are valid scientific reports on the effects of diacylglycerol oil in preventing the accumulation of body fat and obesity, increased sensitivity of cells to insulin, reduced sodium concentration in the blood, ldl and cholesterol and blood pressure in people with atherosclerotic disease. to view or add a comment, sign in 564 followers there's a common misconception that only alcohol damages the liver. however, the reality is more complex. while alcohol consumption can certainly harm the liver, it's not the exclusive culprit. various other factors can also contribute to liver damage, including an unhealthy diet, diabetes, genetic predisposition, obesity, exposure to drugs and toxins, autoimmune diseases, and high cholesterol levels. these factors collectively underscore the importance of maintaining overall health and seeking medical guidance to safeguard liver function. . . . . #shantigopalhospital #fattyliverdisease #fattyliverfighter #fattylivertips #fattylivertreatment #hospitals #hospital #hospitalservices #hospitalsncr #servicehospital #healthcare #healthcareprofessional #doctors #healthcareworkers #mythfact #liverfact to view or add a comment, sign in bioactivator, activation geek, health assurance vs health insurance obesity is at epidemic proportions. glp1 (hormone produced in our gut that helps us know when to eat and when to stop) production has been limited by diseases: • diabetes • obesity • polycystic ovarian syndrome • non alcoholic fatty liver disease diets • with inadequate protein • with inadequate soluble fiber poor gut health it compounds through time and we have a crisis. the number of patients without diabetes but with overweight or obesity who started glucagon like peptide 1 receptor agonist (glp 1ra) treatment in the us has risen from around 21 000 in 2019 to over 174 000 in 2023 a rise of more than 700% a study has found. i have information that could save someone from depending on the synthetic version of glp1. ours activates the gut to make its own glp1 hormone, amoung other positive actions. to view or add a comment, sign in 1,624 followers in the january 2025 issue of mednous (evernow publishing ltd), pulse infoframe founder and ceo, femida gwadry sridhar, explores the critical role of real world data in guiding the responsible use of obesity drugs. her article, "real world data should drive obesity drug use", highlights the importance of collecting and analyzing real world evidence to address the complexities of obesity a condition where poor diet and sedentary lifestyles are significant factors. as obesity treatments gain momentum, ensuring they deliver safe, personalized, and effective outcomes requires robust data to inform clinical and regulatory decisions. this is where real world evidence plays a transformative role. read the full article in mednous to learn more: https://lnkd.in/evnvxsc7 #obesity #glp1 #realworlddata #obesitytreatment to view or add a comment, sign in physician, lead covid 19 autoimmune researcher, #1 amazon best seller, dementia authority, international keynote speaker alcoholic thresholds across the population are likely to be significantly reduced because of subclinical liver inflammation. many people will have noted this change, but not understood the science. the impact of spike protein triggering autoimmune hepatitis can affect alcohol metabolism and detoxification speed. understanding these changes is crucial to prevent inadvertent harm. without a proactive understanding of pandemic outcomes, many people could be inadvertently harmed. stay observant about your thresholds this weekend. #covid #medicine #research to view or add a comment, sign in 35,205 followers high blood levels of tmao (trimethylamine n oxide, a metabolite produced by gut bacteria) could signal future risk of chronic kidney disease, according to a groundbreaking study by cleveland clinic and tufts university. published in the journal of the american society of nephrology, the study highlights the link between tmao and ckd development over time & sheds light on the role of gut microbial metabolites in kidney health. read more about the study here: https://bit.ly/3uoqzju #diaverum #medicalinsight #ckdstudy #kidneyhealth #m42 to view or add a comment, sign in clinical assistant professor of medicine, division of endocrinology diplomate of american board of obesity medicine obesity is associated with higher rates of iron deficiency. obesity leads to ⬆️ inflammation and cytokine release ➡️ stimulates hepcidin synthesis ➡️ increased ferroportin degradation ➡️ decreased iron absorption across intestinal enterocytes. https://buff.ly/3paelzq to view or add a comment, sign in 3,071 followers our principal scientist, liam tremble discusses glp 1r agonists, how they work for those suffering from diabetes, obesity and other metabolic diseases. at poolbeg pharma, we are developing an oral glp 1r agonist, a delivery system which offers a scalable, natural, generally regarded as safe (gras) solution for the oral delivery of api's to specific areas of the gut and into systemic circulation for the #treatment of diabetes, obesity and other metabolic diseases. learn more: https://lnkd.in/enzgn dn #polb #obesity #diabetes #glp1 #metabolicdiseases to view or add a comment, sign in 23,633 followers two new eu funded studies offer new insights to explore diabetes treatment thanks to sib’s expertise in multiomics data integration and analysis: ⚖️ how is glucose balance maintained across organs (#rhapsody project) 🩺 how insulin resistance drives diabetic kidney disease (beat dkd project) an illustration of how data science at sib contributes to better understanding human metabolic health and aiding in the management of conditions like diabetes and obesity. florence mehl, ana rodríguez, ida k.s. meitil, leonore wigger, marco pagni, mark ibberson, bernard thorens, van du t. tran, frederic burdet innovative health initiative (ihi), lipotype #diabetes #multiomics find out more about the discoveries and our approach: to view or add a comment, sign in consultant (medicine) at ministry of health bangladesh obesity is disease now.... so come for holistic approach to findout underlying cause &complications of it.... u know, much better fda approved medicine is available for obesity &metabolic syndrome to view or add a comment, sign in 317 followers create your free account or sign in to continue your search or by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. new to linkedin? join now or new to linkedin? join now by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. linkedin never miss a beat on the app don’t have the app? get it in the microsoft store.

supported by listen to our interview with david ricks and fatima cody stanford. by andrew ross sorkin, evan roberts, dan powell, kelly pieklo, zachary mouton and sarah kessler speaking at the new york times’s dealbook summit, eli lilly’s chief executive and an obesity medicine specialist discussed the potential for wildly popular weight loss drugs to be used to treat many other conditions. by the new york times the health care giant’s david ricks defended the agency’s role in reviewing data and ensuring drug safety. by aimee ortiz genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. that information remained secret. by walt bogdanich and carson kessler eli lilly will now sell cheaper vials of zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. by dani blum the biden administration said it would have saved $6 billion had the new prices been in effect last year. by noah weiland and rebecca robbins mientras los pacientes se plantean fármacos como wegovy, ozempic, zepbound y mounjaro para tratar la obesidad, los expertos afirman que las opciones no son tan sencillas. by gina kolata as patients consider drugs like wegovy, ozempic, zepbound and mounjaro to treat obesity, experts say the choices are not so simple. by gina kolata the drug, kisunla, made by eli lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks. by pam belluck los empleados públicos de virginia occidental que tomaron los fármacos perdieron peso y estaban más sanos, y algunos están abatidos porque el estado está cancelando un programa para ayudar a pagarlos. by oliver whang

at a glance the us preventive services task force published in jama a recommendation statement on interventions for high body mass index in children and adolescents. simar bajaj at newscientist on glp 1s’ unexpected effects on the brain, to treat depression, anxiety, addiction and alzheimer’s. jama pediatrics publishes the impact of financial incentives on improved outcomes of a dietary intervention among 126 adolescents with severe obesity. zealand pharma drug petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, with the potential of lower side effects. news the us preventive services task force published in jama a recommendation statement on interventions for high body mass index in children and adolescents. they ‘…commissioned a systematic review to evaluate the evidence on interventions (behavioral counseling and pharmacotherapy) for weight loss or weight management in children and adolescents that can be provided in or referred from a primary care setting.’ the outcome was for clinicians to ‘…provide or refer children and adolescents 6 years or older with a high bmi to comprehensive, intensive behavioral interventions. this is in the context that almost 20% of children and adolescents aged 2 to 19 years in the us have a bmi at or above the 95th percentile for age and sex, based on centers for disease control and prevention (cdc) growth charts from 2000. a comprehensive, intensive behavioral interventions is defined as comprising at least 26 contact hours or more that include supervised physical activity sessions for up to 1 year. the usptf found the totality of the evidence on medications for weight loss to be inadequate. in addition, the uspstf did not review evidence for bariatric surgery, but it remains another important treatment for children and adolescents with severe obesity, supported by several professional recommendations, and based on high quality longitudinal safety and efficacy data. opinion simar bajaj writes at newscientist on glp 1s’ unexpected effects on the brain, opening up potential new ways to treat depression, anxiety, addiction and alzheimer’s. bajaj adds ‘…there are hints that these drugs could be repurposed to treat depression, anxiety, addiction and even certain eating disorders [mediated] …through direct action on the brain.’ gina kolata at the new york times on doctors test the limits of what obesity drugs can fix. the article notes ‘…obesity first doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish.’ so true! from blood pressure, cholesterol, arthritis and sleep apnea, to diabetes, kidney disease, and on to depression, addiction, schizophrenia, parkinson’s disease and alzheimer’s disease… with potential impact on a reduced risk of common cancers too. a significant proportion of overweight or obese patients don’t find pharmaceutical ads about weight management products relatable, says andrea park in fierce pharma. the survey, conducted by phreesia and klick health, comprised nearly 3,000 individuals, with ‘…one third said they don’t rely at all on a healthcare provider or specialist to help with their weight management.’ in addition, ‘…fewer than 10% said they were currently using over the counter or prescription medications to help with weight loss.’ there were also ‘…low levels of trust in pharma ads when it came to looking for information about weight management.’ data jama pediatrics publishes the impact of financial incentives on improved outcomes of a dietary intervention among 126 adolescents with severe obesity. in addition to pre portioned, calorie controlled meals of 1200 kcals/day, subjects in the intervention group received a $20 gift card for every 0.5% they lost from their body weight at the start of the study, up to 52 weeks. those getting the gift card had a reduction in bmi of about 7%, compared to around 1% for those in the control group. ted kyle at conscienhealth adds ‘…money for weight loss might not be the best strategy for helping teens cope with severe obesity. the lancet diabetes & endocrinology publishes on associations between bmi and hospital resource use in patients hospitalized for covid 19 in england. from almost sixty thousand patients admitted to hospital with covid 19 between april 1, 2020, and dec 31, 2021, those living with obesity [bmi >30] had longer hospital stays, were more likely to be admitted to icu, with hospital costs estimated to be £2,736 [or about $3,458] higher. we have known that excess weight is a major risk factor for severe disease after infection with sars cov 2, with the ability to inform national resource allocation to match hospital capacity to areas where bmi profiles indicate higher demand. in america, the centers for disease control and prevention in atlanta, ga reviewed over 100,000 adults and reported overweight and obesity were associated with higher cost of care, and obesity was associated with longer hospital stays too. zealand pharma drug petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, with the potential of lower side effects, as per the phase 1b multiple ascending dose (mad) trial. david kendall, zealand’s chief medical officer said ‘…these results support our conviction that petrelintide is very well tolerated and can potentially play an important role as an alternative to incretin based therapies for the management of overweight and obesity.’ amylin is a hormone produced in pancreatic beta cells and co secreted with insulin in response to food intake. notably, the study was from just 48 participants, and will require considerably more data to be developed into a prescription medication. zealand pharma aims to rapidly progress the clinical development of petrelintide and initiate a phase 2b clinical trial later in 2024. additional topics modern healthcare inside weightwatchers' shift on wegovy, mounjaro, other glp 1s stat on novo nordisk ceo agrees to bernie sanders’ demand to testify on ozempic, wegovy prices an open letter from eli lilly and company regarding certain practices related to mounjaro® and zepbound a new lancet series urges screen early in pregnancy for gestational diabetes no posts ready for more?
supported by “obesity first” doctors say they start with one medication, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish. by gina kolata lesa walton suffered for years with rheumatoid arthritis. “it was awful,” said ms. walton, 57, who lives in wenatchee, wash. “i kept getting sicker and sicker.” she also had high blood pressure, and she was obese. doctors told her to diet and exercise, which she did, to no avail. then she found a doctor who prescribed wegovy, one of the new obesity drugs. not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure. her new doctor, dr. stefie deeds, an internist and obesity medicine specialist in private practice in seattle, said that ms. walton exemplifies a growing movement in obesity medicine. proponents call it “obesity first.” the idea is to treat obesity with medications approved for that use. as obesity comes under control, they note, the patient’s other chronic diseases tend to improve or go away. “we are treating the medical condition of obesity and its related complications at the same time,” dr. deeds said.

 this post was originally published on this site ‘obesity first’ doctors say they start with one pill, to treat obesity, and often find other chronic diseases, like rheumatoid arthritis, simply vanish lesa walton suffered for years with rheumatoid arthritis. “it was awful,” said ms. walton, 57, who lives in wenatchee, wash. “i kept getting sicker and sicker.” she also had high blood pressure, and she was obese. doctors told her to diet and exercise, which she did, to no avail. then she found a doctor who prescribed wegovy, one of the new obesity drugs. not only did she lose more than 50 pounds, she said; her arthritis cleared up, and she no longer needed pills to lower her blood pressure.